Biology subjects

Siewert, A.

Publications and source records attributed to Siewert, A..

3 recordsLinked to original sources

bioRxiv2026

Time-resolved inference of gene regulatory networks underlying human cranial neural crest development suggests novel risk genes for orofacial clefting.

Cranial neural crest cells (CNCCs) play a central role in shaping the human head and face. Aberrant CNCC differentiation contributes to craniofacial birth defects, particularly non-syndromic cleft lip with or without cleft palate (nsCL/P), one of the most common congenital disorders. Although the number of genetic variants associated with this condition is steadily increasing, it remains challenging to determine if and how these variants may contribute to disease development. The majority of these variants lie within non-coding regulatory elements that govern cell-type and stage-specific gene expression, which is orchestrated by dynamic gene regulatory networks (GRNs). Despite extensive work in model organisms, a time-resolved, multi-omics perspective of GRNs controlling CNCC differentiation in a human system is still lacking. To fill this gap, we generated paired transcriptomic and chromatin accessibility data at four timepoints during in vitro differentiation of CNCCs derived from human induced pluripotent stem cells. Integrating these two modalities enabled time-resolved inference of GRNs and identification of dynamic regulatory relationships, including stage-specific roles of core transcription factors. Leveraging these time-resolved GRNs, we mapped 29 nsCL/P associated variants linked to 70 putative target genes, with 40 located outside the associated genomic loci, suggesting novel distal regulatory relationships. Integration of these data with complementary time-course scRNA-seq data revealed an ectomesenchymal-biased subpopulation of CNCCs as particularly sensitive to genetic variants associated with nsCL/P. We provide a time-resolved inference of GRN in human CNCC differentiation, allowing us to determine the dynamics of stage-specific core regulatory programs that are otherwise missed in analyses based on a single time snapshot. To our knowledge, the data represent the first multi-omics map of human CNCC with temporal resolution, which expands the understanding of early human craniofacial development, refines variant-to-gene assignment, prioritizes candidate risk genes and cell states relevant to nsCL/P. Our findings demonstrate the relevance of studying the dynamics upon differentiation rather than just one fixed timepoint and offer a valuable basis for further investigation of non-coding variation in CNCC-related disorders.

bioinformatics↗

bioRxiv2025

A short linear motif, conserved from yeast to human, binds to members of the Spa2/GIT1 family of cortical scaffold proteins

Tip growth is closely tied to fungal pathogenicity. Spa2, a multi-domain protein and member of the polarisome, orchestrates tip growth in yeast and other fungi. We identified a conserved short linear motif in the RabGAPs Msb3 and Msb4, and the MAP kinase kinase Ste7 and Mkk1, which mediates their interaction with Spa2. AlphaFold predictions suggest that these initially unstructured motifs adopt an alpha-helical conformation upon binding to the hydrophobic cleft of Spa2s N-terminal domain. Altering the predicted key contact residues in either Spa2 or the motif reduces complex stability. Such mutations also cause mis-localization of Msb3, Msb4, and Ste7 within the cell. Deleting the motif in Msb3 or Msb4 abolishes tip-directed growth of the yeast bud. Protein assemblies that spatially confine secretion to specific membrane regions are a common feature of eukaryotic cells. Accordingly, Spa2-motif complexes were predicted in orthologs and paralogs across selected Opisthokonta, including pathogenic fungi and humans. A search for functional motifs in conformationally flexible regions of all yeast proteins identified Dse3 as a novel Spa2-binding partner.

cell biology↗

bioRxiv2020

Mechanism of SARS-CoV-2 polymerase inhibition by remdesivir

Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients1-4. The active form of remdesivir acts as a nucleoside analogue and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-25-7. Remdesivir is incorporated by the RdRp into the growing RNA product and allows for addition of three more nucleotides before RNA synthesis stalls6,8. Here we use synthetic RNA chemistry, biochemistry and cryo-electron microscopy to establish the molecular mechanism of remdesivir-induced RdRp stalling. We show that addition of the fourth nucleotide following remdesivir incorporation into the RNA product is impaired by a barrier to further RNA translocation. This translocation barrier causes retention of the RNA 3-nucleotide in the substrate-binding site of the RdRp and interferes with entry of the next nucleoside triphosphate, thereby stalling RdRp. In the structure of the remdesivir-stalled state, the 3-nucleotide of the RNA product is matched with the template base, and this may prevent proofreading by the viral 3-exonuclease that recognizes mismatches9,10. These mechanistic insights should facilitate the quest for improved antivirals that target coronavirus replication.

biochemistry↗